Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
List view / Grid view
GT Biopharma Inc.
GTB-3550 TriKE™ monotherapy was found to restore natural killer cell function and immune surveillance in relapsed or refractory AML and MDS cancer patients.